孟鲁司特钠对肺炎支原体感染诱发哮喘早期干预治疗的临床研究

A Clinical Investigation on the early intervention treatment on mycoplasma pneumonia induced asthma with Montelukast sodium

目的观察孟鲁司特钠(白三烯受体拮抗剂,顺尔宁,默沙东)早期干预治疗肺炎支原体感染对预防哮喘的作用。方法选择2008年2月至2009年4月在本院儿科住院的150例肺炎支原体感染患儿(符合入选标准),随机分为观察组和对照组,两组均采用常规抗支原体的基础治疗,观察组同时予以孟鲁司特钠治疗四周后观察哮喘的发病情况。结果肺炎支原体感染后常规应用大环内酯类抗生素抗支原体及对症治疗,辅以孟鲁司特钠进行治疗后,哮喘的发病率明显低于对照组。结论选择孟鲁司特钠可阻断肺炎支原体感染后作为变应原刺激呼吸道的炎症反应,降低气道的高反应性,减少粘液分泌,缓解支气管痉挛,降低哮喘的发病率。

Objective To investigate the clinical effective of the early intervention treatment on mycoplasma pneumoria induced asthma with Montelukast sodium. Methods Totally 150 children infected with mycoplasma pneumoniae（ Meet the inclusion criteria）from February 2008 to April 2009 in pediatrics department of our hospital were selected to randomly assign into the observation group and the control group. Both groups took conventional antimycoplasma therapy, but the observation group simultaneously took montelukast for 4 weeks, then observed the incidence of asthma. Results Mycoplasma pneumonia infection after application of conventional anti-mycoplasma therapy （mecrolide antibiotics） and symptomatic treatment, supplemented by montelukast special treatment, the incidence of asthma in the observation group was significantly lower than that of the control group. Conclusions Montelukast can block mycoplasma pneumoniae that stimulates the inflammatory response of the respiratory tract as an allergen after infection, lower airway hyperresponsiveness, reduce mucus secretion, ease bronchial spasm, reduce the incidence of asthma.